Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View Item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

CD52 expression in T-cell large granular lymphocyte leukemia - Implications for treatment with alemtuzumab

Thumbnail
Publication Date
2005-05
ICR Author
Catovsky, Daniel
Matutes, Estella
Morilla, Alison
Osuji, NNenna
Author
Osuji, N
Del Giudice, I
Matutes, E
Morilla, A
Owusu-Ankomah, K
Morilla, R
Dunlop, A
Catovksy, D
Type
Journal Article
Metadata
Show full item record
Abstract
Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we documented the expression of CD52 in 100% of abnormal cells in T-cell LGL leukemia (n = 11) and natural killer (NK) cell LGL leukemia (n = 2), and showed no significant difference in CD52 expression between T-cell prolymphocytic leukemia (PLL) and T-cell LGL leukemia. Higher CD52 expression has been noted in responders to alemtuzumab in T-cell PLL and in chronic lymphocytic leukemia (CLL), a B-cell disorder. The strong and consistent expression of CD52 shown here highlights the potential role of alemtuzumab in the treatment of refractory T-cell LGL leukemia and possibly aggressive NK cell leukemia.
URL
https://repository.icr.ac.uk/handle/internal/2577
Collections
  • Clinical Studies
  • Molecular Pathology
Version of record
10.1080/10428190500052156
Research team
Molecular Haematology (including Cytogenetics Group and Cell Markers)
Language
English
License start date
2005-05
Citation
LEUKEMIA & LYMPHOMA, 2005, 46 pp. 723 - 727
Publisher
TAYLOR & FRANCIS LTD

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.